首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Possible in vivo 5-HT reuptake blocking properties of 8-OH-DPAT assessed by measuring hippocampal extracellular 5-HT using microdialysis in rats.
【2h】

Possible in vivo 5-HT reuptake blocking properties of 8-OH-DPAT assessed by measuring hippocampal extracellular 5-HT using microdialysis in rats.

机译:通过使用大鼠微透析测量海马细胞外5-HT评估了8-OH-DPAT的体内5-HT再摄取阻断特性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. The 5-hydroxytryptamine (5-HT)1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), has been shown to label 5-HT reuptake sites. 2. To study the functional consequences of this property, the effects of 8-OH-DPAT were compared with those of the 5-HT reuptake inhibitors, paroxetine and clomipramine, and of the 5-HT1A receptor agonist flesinoxan, in vitro on 5-HT reuptake, and in vivo on the extracellular concentration of 5-HT by use of microdialysis, in rat hippocampus. Because 5-HT reuptake inhibitors reportedly attenuate the ability of (+)-fenfluramine to increase the extracellular concentration of 5-HT, the possible reversal of these effects of 8-OH-DPAT and by paroxetine were examined. 3. 8-OH-DPAT, paroxetine and clomipramine inhibited [3H]-5-HT reuptake in rat hippocampal synaptosomes (pIC50: 6.00, 8.41 and 7.00, respectively). In contrast, flesinoxan did not alter 5-HT reuptake (pIC50 < 5). 4. 8-OH-DPAT (10 and 100 microM), paroxetine (0.1 microM) and clomipramine (1 microM), administered through the dialysis probe, significantly increased the hippocampal extracellular concentration of 5-HT. In contrast, flesinoxan (100 microM) did not alter extracellular 5-HT. Moreover, the effects of 100 microM 8-OH-DPAT were not blocked by the 5-HT1A receptor antagonist, WAY-100635 (0.16 mg kg-1, s.c.). 5. The increase in extracellular 5-HT induced by 10 mg kg-1, i.p., (+)-fenfluramine was prevented not only by 0.1 microM paroxetine, but also by 100 microM 8-OH-DPAT. In addition, systemic administration of 10 mg kg-1, but not 2.5 mg kg-1, i.p. 8-OH-DPAT attenuated the increase in extracellular 5-HT induced by 2.5 mg kg-1, i.p., (+)-fenfluramine. 6. These findings suggest that the increase in extracellular 5-HT produced by local administration of 8-OH-DPAT does not involve its 5-HT1A receptor agonist properties, but may result, at least in part, from its 5-HT reuptake blocking properties.
机译:1. 5-羟色胺(5-HT)1A受体激动剂8-羟-2-(二正丙基氨基)四氢化萘(8-OH-DPAT)已被证明可以标记5-HT再摄取位点。 2.为了研究该特性的功能后果,将5-OH-DPAT的作用与5-HT再摄取抑制剂帕罗西汀和氯米帕明以及5-HT1A受体激动剂flesinoxan的体外作用进行了比较,比较了5- HT再摄取,以及在大鼠海马体内通过微透析对5-HT的细胞外浓度的体内作用。由于据报道5-HT再摄取抑制剂减弱了(+)-芬氟拉明增加5-HT细胞外浓度的能力,因此研究了8-OH-DPAT和帕罗西汀逆转这些作用的可能。 3. 8-OH-DPAT,帕罗西汀和氯米帕明抑制大鼠海马突触小体中的[3H] -5-HT再摄取(pIC50分别为6.00、8.41和7.00)。相比之下,flesinoxan不会改变5-HT再摄取(pIC50 <5)。 4.通过透析探针给药的8-OH-DPAT(10和100 microM),帕罗西汀(0.1 microM)和氯米帕明(1 microM)显着提高了海马5-HT的浓度。相反,flesinoxan(100 microM)不会改变细胞外5-HT。此外,5-HT1A受体拮抗剂WAY-100635(0.16 mg kg-1,s.c.)不能阻断100 microM 8-OH-DPAT的作用。 5.通过0.1μM的帕罗西汀和通过100μM的8-OH-DPAT防止了10mg kg-1(即,(+)-芬氟拉明)诱导的细胞外5-HT的增加。另外,全身给药10mg kg-1,而不是2.5mg kg-1。 8-OH-DPAT减弱了由2.5mg kg-1,即(+)-芬氟拉明诱导的细胞外5-HT的增加。 6.这些发现表明,局部施用8-OH-DPAT所产生的细胞外5-HT的增加不涉及其5-HT1A受体激动剂的性质,但可能至少部分是由于其5-HT再摄取的阻断属性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号